Koers Tekla Life Sciences Investors Nyse
Aandelen
US4040531000
Gesloten eindfondsen
slotkoers
Andere beurzen
|
||
- USD | - |
Omzet 2021 | 2,29 mln. 2,14 mln. | Omzet 2022 | 3,02 mln. 2,83 mln. | Marktkapitalisatie | 343 mln. 322 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2021 | 64 mln. 59,98 mln. | Nettowinst (verlies) 2022 | -105 mln. -98,41 mln. | EV/omzet 2021 | 225 x |
Nettoschuld 2021 | 10,04 mln. 9,41 mln. | Nettoschuld 2022 | 11,09 mln. 10,39 mln. | EV/omzet 2022 | 117 x |
K/w-verhouding 2021 |
7,95
x | K/w-verhouding 2022 |
-3,35
x | Werknemers | - |
Dividendrendement 2021 |
8,03% | Dividendrendement 2022 |
10,8% | Vrij verhandelbaar | 99,99% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Dan Omstead
PSD | President | 71 | 01-01-01 |
Jason Akus
CTO | Chief Tech/Sci/R&D Officer | - | - |
Laura Woodward
CMP | Compliance Officer | 56 | 01-01-09 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 74 | 01-01-07 | |
Dan Omstead
PSD | President | 71 | 01-01-01 |
Jeffrey Bailey
BRD | Director/Board Member | 62 | 01-01-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+2,90% | 12,63 mld. | |
+6,03% | 9,1 mld. | |
-4,26% | 5,38 mld. | |
+4,00% | 5,36 mld. | |
+5,91% | 5,19 mld. | |
+10,02% | 4,47 mld. | |
+14,35% | 4,44 mld. | |
+1,29% | 4 mld. | |
+3,58% | 3,86 mld. |